An inactivating CYLD mutation promotes skin tumor progression by conferring enhanced proliferative, survival and angiogenic properties to epidermal cancer cells - PubMed (original) (raw)
. 2010 Dec 16;29(50):6522-32.
doi: 10.1038/onc.2010.378. Epub 2010 Sep 13.
Affiliations
- PMID: 20838385
- DOI: 10.1038/onc.2010.378
An inactivating CYLD mutation promotes skin tumor progression by conferring enhanced proliferative, survival and angiogenic properties to epidermal cancer cells
J P Alameda et al. Oncogene. 2010.
Abstract
In this study, we demonstrate that the expression in tumorigenic epidermal cells of a catalytically inactive form of CYLD (CYLD(C/S)) that mimics the identified mutations of cyld in human tumors and competes with the endogenous CYLD results in enhanced cell proliferation and inhibition of apoptosis; it also stimulates cell migration and induces the expression of angiogenic factors, including vascular endothelial growth factor-A. Altogether, these characteristics indicate an increased oncogenicity of the tumorigenic epidermal CYLD(C/S) mutant cells in vitro. Moreover, we show the increase in malignancy of epidermal squamous cell carcinomas that express the CYLD(C/S) transgene in an in vivo xenograft model. Tumors carrying the mutated CYLD(C/S) exhibit a fast growth, are poorly differentiated and present a robust angiogenesis. CYLD(C/S) tumors are also characterized by their elevated proliferation rate and decreased apoptosis. In contrast with previous studies showing the development of benign tumors by mutations in the CYLD gene, here we provide evidence that the occurrence of mutations in the CYLD gene in tumorigenic epidermal cells (carrying previous mutations) increases the aggressiveness of carcinomas, mainly through enhancement of the expression of angiogenic factors, having therefore a key role in epidermal cancer malignancy.
Similar articles
- A critical role for ras-mediated, epidermal growth factor receptor-dependent angiogenesis in mouse skin carcinogenesis.
Casanova ML, Larcher F, Casanova B, Murillas R, Fernández-Aceñero MJ, Villanueva C, Martínez-Palacio J, Ullrich A, Conti CJ, Jorcano JL. Casanova ML, et al. Cancer Res. 2002 Jun 15;62(12):3402-7. Cancer Res. 2002. PMID: 12067982 - Ganoderma tsugae extract inhibits expression of epidermal growth factor receptor and angiogenesis in human epidermoid carcinoma cells: In vitro and in vivo.
Hsu SC, Ou CC, Chuang TC, Li JW, Lee YJ, Wang V, Liu JY, Chen CS, Lin SC, Kao MC. Hsu SC, et al. Cancer Lett. 2009 Aug 18;281(1):108-16. doi: 10.1016/j.canlet.2009.02.032. Epub 2009 Mar 29. Cancer Lett. 2009. PMID: 19332363 - Oncogene activation and tumor suppressor gene inactivation during multistage mouse skin carcinogenesis.
Bowden GT, Schneider B, Domann R, Kulesz-Martin M. Bowden GT, et al. Cancer Res. 1994 Apr 1;54(7 Suppl):1882s-1885s. Cancer Res. 1994. PMID: 8137304 Review. - CYLD: a deubiquitination enzyme with multiple roles in cancer.
Massoumi R. Massoumi R. Future Oncol. 2011 Feb;7(2):285-97. doi: 10.2217/fon.10.187. Future Oncol. 2011. PMID: 21345146 Review.
Cited by
- Genomic insights into molecular profiling of thymic carcinoma: a narrative review.
Takata S. Takata S. Mediastinum. 2024 Jun 5;8:39. doi: 10.21037/med-24-5. eCollection 2024. Mediastinum. 2024. PMID: 39161584 Free PMC article. Review. - The Potential of Cylindromatosis (CYLD) as a Therapeutic Target in Oxidative Stress-Associated Pathologies: A Comprehensive Evaluation.
Huang Z, Tan Y. Huang Z, et al. Int J Mol Sci. 2023 May 6;24(9):8368. doi: 10.3390/ijms24098368. Int J Mol Sci. 2023. PMID: 37176077 Free PMC article. Review. - Genomic Characterization of Prostatic Basal Cell Carcinoma.
Low JY, Ko M, Hanratty B, Patel RA, Bhamidipati A, Heaphy CM, Sayar E, Lee JK, Li S, De Marzo AM, Nelson WG, Gupta A, Yegnasubramanian S, Ha G, Epstein JI, Haffner MC. Low JY, et al. Am J Pathol. 2023 Jan;193(1):4-10. doi: 10.1016/j.ajpath.2022.09.010. Epub 2022 Oct 26. Am J Pathol. 2023. PMID: 36309102 Free PMC article. - A Novel Prognostic Signature Associated with Immunotherapeutic Response for Hepatocellular Carcinoma.
Jin X, Wang J. Jin X, et al. Front Surg. 2022 Jul 5;9:905897. doi: 10.3389/fsurg.2022.905897. eCollection 2022. Front Surg. 2022. PMID: 35865037 Free PMC article. - CYLD Inhibits the Development of Skin Squamous Cell Tumors in Immunocompetent Mice.
Alameda JP, García-García VA, López S, Hernando A, Page A, Navarro M, Moreno-Maldonado R, Paramio JM, Ramírez Á, García-Fernández RA, Casanova ML. Alameda JP, et al. Int J Mol Sci. 2021 Jun 23;22(13):6736. doi: 10.3390/ijms22136736. Int J Mol Sci. 2021. PMID: 34201751 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical